Answers are grounded in this paper and cite their sources.
Purpose Meningiomas may express estrogen/progesterone receptors (ER/PR), but hormonal risk is poorly characterized. We characterized association between progesterone supplementation and tumor-related visual deficits in premenopausal women receiving radiation for meningioma. Methods We performed a retrospective case-control study with primary endpoint of visual deficit prior to radiation for intracranial meningioma in women ≤55 receiving radiation at one academic center from 2012-2025. Records were reviewed to determine risk factors including age, race, grade, neurofibromatosis / prior radiation (NF/PriorRT), gravida, unopposed progesterone use, skull base location, and time from diagnosis to radiation. All available pathology specimens were tested for ER/PR. Logistic regression was performed to analyze associations with visual deficit. Results 70 women with median age 45 were included. 32 patients (44%) had meningioma grade ≥2; 51 (73%) had skull base tumors; 8 (11%) had NF/Prior RT. 30 women (43%) had used unopposed progesterone; 16 (23%) used depo-medroxyprogesterone acetate (Depo-Provera) specifically. Visual deficit was present in 38 patients (54%) and was associated with unopposed progesterone use (p=0.001, OR 8.3), black race (p=0.024, OR 5.4), and skull base location (p=0.003, OR 10.3) on multivariable analysis. Proportion using unopposed progesterone was 63% vs. 19% in patients with vs. without visual deficit, respectively (chi-sq p<0.001). 92% of progesterone exposures preceded visual deficit (in those with visual deficit). Only 5/57 (9%) original pathology reports discussed ER/PR status; 42 after pathologic re-analysis. PR was positive in 40 (95%) and ER in 1 (2%). In this subset, there was a nonsignificant trend to an association between progesterone receptor staining % and visual deficit on multivariable analysis (p=0.068, OR 1.03). Conclusions Progesterone use was associated with meningioma-related visual deficit in women referred for radiotherapy. Providers should be aware of this potential risk factor and further study is warranted.
No takes yet. Share an insight, caveat, or question.
Bailey et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: